doxapram
Trade name: dopram
Approved
Jun 23, 1965
Doxapram is an analeptic agent (a stimulant of the central nervous system). The respiratory stimulant action is manifested by an increase in tidal volume associated with a slight increase in respiratory rate. A pressor response may result following doxapram administration. Provided there is no impairment of cardiac function, the pressor effect is more marked in hypovolemic than in normovolemic states. The pressor response is due to the improved cardiac output rather than peripheral vasoconstriction. Following doxapram administration, an increased release of catecholamines has been noted. Doxapram produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. It is thought to stimulate the carotid body by inhibiting certain potassium channels. Used as temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. — NCATS
Clinical trial activity
8 trials · 17 clinical orgs · 5 marketing orgs
Earliest trial started Nov 1, 2006 (NCT00389909)
Timeline
1960s
- Jun 23, 1965
Hikma — Earliest FDA Approval
- Jun 23, 1965
West-Ward Pharmaceutical — NDA Secondary Org
- Jun 23, 1965
Hikma — NDA Secondary Org
- Jun 23, 1965
Hikma — NDA Organization
- Jun 23, 1965
Hikma — Marketing Organization
1990s
- Jan 30, 1992
Watson Pharmaceuticals — Marketing Organization
2000s
- Jan 10, 2003
Athenex, Inc. — Marketing Organization
- Jan 10, 2003
Chartwell Pharmaceuticals — Marketing Organization
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
KCNK3 blocker
KCNK9 blocker
Approval history
- approvedJun 23, 1965
Chemistry & pharmacology
SMILES
CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O- Mol. weight
- 432.99 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL3989519 ↗
- WikipediaDoxapram ↗
- NCATS94F3830Q73 ↗
- ChEMBLCHEMBL1754 ↗
- ChEMBLCHEMBL1200876 ↗
Also known as
- 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone
- 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone
- ahr-619
- ahr-619
- dopram
- dopram
- dopram
- dopram
- doxapram
- doxapram
- doxapram
- doxapram
- doxapram
- doxapram
- doxapram
- doxapram
- (+-)-doxapram
- (+-)-doxapram
- doxapram hcl
- doxapram hcl
- doxapram hcl
- doxapram hydrochloride
- doxapram hydrochloride
- doxapram hydrochloride
- doxapram hydrochloride
- doxapram hydrochloride hydrate
- doxapram hydrochloride hydrate
- doxapram hydrochloride hydrate
- doxapram hydrochloride hydrate
- doxapram hydrochloride hydrate
- doxapram hydrochloride hydrate
- doxapramum
- doxapramum
- stimulexin
- stimulexin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06585163 | Phase 1 | Sep 30, 2024 | National Institute on Drug Abuse (NIDA), Quivive Pharma, Inc., The Cleveland Clinic |
| NCT04430790 | Phase 3 | Jun 15, 2020 | Erasmus University Rotterdam, Katholieke Universiteit Leuven, Nederlands Neonataal Netwerk (N3), the Netherlands, University of Amsterdam |
| NCT03894189 | N/A | May 31, 2019 | Beni Suef University |
| NCT02171910 | Phase 4 | Oct 1, 2016 | University of Helsinki |
| NCT02820025 | N/A | Oct 1, 2015 | Ningxia Medical University |
| NCT01022151 | Phase 2 | Nov 1, 2007 | King Faisal University |
| NCT00477451 | Phase 2 | May 1, 2007 | Alexza Pharmaceuticals, Inc., Columbia University, Icahn School of Medicine at Mount Sinai, State University of New York, Brooklyn |
| NCT00389909 | Phase 4 | Nov 1, 2006 | Maternite Regionale Universitaire, University of Lorraine |
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alexza Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2007 |
| Beni Suef University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 0 | 1 | 2020 |
| King Faisal University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Maternite Regionale Universitaire | Academic/Hospital | 1 | 1 | 1 | 2006 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2024 |
| Nederlands Neonataal Netwerk (N3), the Netherlands | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Ningxia Medical University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Quivive Pharma, Inc. | For profit | 1 | 1 | 1 | 2024 |
| State University of New York, Brooklyn | Academic/Hospital | 1 | 0 | 1 | 2007 |
| The Cleveland Clinic | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Helsinki | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Lorraine | Academic/Hospital | 1 | 0 | 1 | 2006 |
Marketing (7)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Athenex, Inc. | For profit | MKTG | Jan 10, 2003 |
| Chartwell Pharmaceuticals | For profit | MKTG | Jan 10, 2003 |
| Hikma | For profit | NDA2 | Jun 23, 1965 |
| Hikma | For profit | NDA | Jun 23, 1965 |
| Hikma | For profit | MKTG | Jun 23, 1965 |
| Watson Pharmaceuticals | For profit | MKTG | Jan 30, 1992 |
| West-Ward Pharmaceutical | For profit | NDA2 | Jun 23, 1965 |